These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 33694050)

  • 21. Comparison of slow and forced vital capacities on ability to predict survival in ALS.
    Pinto S; de Carvalho M
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):528-533. PubMed ID: 28741375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis.
    Agnello L; Colletti T; Lo Sasso B; Vidali M; Spataro R; Gambino CM; Giglio RV; Piccoli T; Bivona G; La Bella V; Ciaccio M
    Eur J Neurol; 2021 Jun; 28(6):1868-1875. PubMed ID: 33638255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis.
    Lanznaster D; Bejan-Angoulvant T; Patin F; Andres CR; Vourc'h P; Corcia P; Blasco H
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 May; 20(3-4):199-206. PubMed ID: 30961401
    [No Abstract]   [Full Text] [Related]  

  • 24. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.
    Thouvenot E; Demattei C; Lehmann S; Maceski-Maleska A; Hirtz C; Juntas-Morales R; Pageot N; Esselin F; Alphandéry S; Vincent T; Camu W
    Eur J Neurol; 2020 Feb; 27(2):251-257. PubMed ID: 31437330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis.
    Jahandideh S; Taylor AA; Beaulieu D; Keymer M; Meng L; Bian A; Atassi N; Andrews J; Ennist DL
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):294-302. PubMed ID: 29260584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease.
    Beswick E; Fawcett T; Hassan Z; Forbes D; Dakin R; Newton J; Abrahams S; Carson A; Chandran S; Perry D; Pal S
    J Neurol; 2022 Dec; 269(12):6254-6268. PubMed ID: 35945397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study.
    Kjældgaard AL; Pilely K; Olsen KS; Jessen AH; Lauritsen AØ; Pedersen SW; Svenstrup K; Karlsborg M; Thagesen H; Blaabjerg M; Theódórsdóttir Á; Elmo EG; Møller AT; Bonefeld L; Berg M; Garred P; Møller K
    BMC Neurol; 2021 Apr; 21(1):164. PubMed ID: 33865343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
    Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
    Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
    Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis.
    Mandrioli J; Ferri L; Fasano A; Zucchi E; Fini N; Moglia C; Lunetta C; Marinou K; Ticozzi N; Drago Ferrante G; Scialo C; Sorarù G; Trojsi F; Conte A; Falzone YM; Tortelli R; Russo M; Sansone VA; Mora G; Silani V; Volanti P; Caponnetto C; Querin G; Monsurrò MR; Sabatelli M; Chiò A; Riva N; Logroscino G; Messina S; Calvo A
    Eur J Neurol; 2018 Jun; 25(6):861-868. PubMed ID: 29512869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics, course, and outcomes of amyotrophic lateral sclerosis overlapping with pregnancy: a systematic review of 38 published cases.
    Hamad AA; Amer BE; Al Mawla AM; Goufa E; Abdelwahab MM; Serag I
    Neurol Sci; 2023 Dec; 44(12):4219-4231. PubMed ID: 37587387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.
    Dalbello-Haas V; Florence JM; Krivickas LS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005229. PubMed ID: 18425913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
    Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
    Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study.
    Van Laere K; Vanhee A; Verschueren J; De Coster L; Driesen A; Dupont P; Robberecht W; Van Damme P
    JAMA Neurol; 2014 May; 71(5):553-61. PubMed ID: 24615479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic Alteration and Amyotrophic Lateral Sclerosis Outcome: A Systematic Review.
    Brito MD; da Silva GFG; Tilieri EM; Araujo BG; Calió ML; Rosenstock TR
    Front Neurol; 2019; 10():1205. PubMed ID: 31824397
    [No Abstract]   [Full Text] [Related]  

  • 38. Coping in people with amyotrophic lateral sclerosis and motor neuron disease: Systematic review.
    Oh J; An J; Park K
    J Clin Nurs; 2021 Jul; 30(13-14):1838-1853. PubMed ID: 33555628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for cognitive and behavioral change in amyotrophic lateral sclerosis/motor neuron disease: a systematic review of validated screening methods.
    Simon N; Goldstein LH
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):1-11. PubMed ID: 30585510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.
    Conde B; Winck JC; Azevedo LF
    Neuroepidemiology; 2019; 53(1-2):73-83. PubMed ID: 31117082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.